Researchers published a next‑generation CAR‑T design that selectively leverages tumor features and microenvironmental cues to improve therapeutic specificity and efficacy. The study outlines strategies to direct CAR‑T activity toward tumor‑unique antigens and adapt engineered receptors to heterogeneous tumor landscapes. The work combines antigen sensing, modular receptor engineering, and microenvironment‑responsive elements; these technical refinements aim to reduce off‑tumor toxicity and enhance persistence. The findings advance translational approaches for solid‑tumor CAR‑T programs and inform clinical engineering of adaptive cell therapies.